Literature DB >> 29132760

Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030.

Mark W Sonderup1, Mary Afihene2, Reidwaan Ally3, Betty Apica4, Yaw Awuku5, Lina Cunha6, Geoffrey Dusheiko7, Neliswa Gogela8, Marie-Jeanne Lohouès-Kouacou9, Phillip Lam10, Olufunmilayo Lesi11, Papa Saliou Mbaye12, Emmanuel Musabeyezu13, Betty Musau14, Olesegun Ojo15, John Rwegasha16, Barbara Scholz17, Abate B Shewaye18, Christian Tzeuton19, Chris Kassianides20, C Wendy Spearman8.   

Abstract

In 2016, WHO adopted a strategy for the elimination of viral hepatitis by 2030. Africa, and more specifically, sub-Saharan Africa, carries a substantial portion of the global burden of viral hepatitis, especially chronic hepatitis B and hepatitis C virus infections. The task that lies ahead for sub-Saharan Africa to achieve elimination is substantial, but not insurmountable. Major developments in the management of hepatitis C have put elimination within reach, but several difficulties will need to be navigated on the path to elimination. Many of the challenges faced are unique to sub-Saharan Africa and the development of strategies is complicated by a scarcity of good data from countries and regions within sub-Saharan Africa. However, this hindrance should not act as a barrier to delay interventions in screening, detection, and linkage to care. Moreover, by sharing experiences from across sub-Saharan Africa, countries can create supranational synergies to develop their programmes and work together in a more cohesive manner to tackle the burden of hepatitis C in sub-Saharan Africa. In this Series paper, several issues related to hepatitis C in sub-Saharan Africa are addressed, including prevalence, risk factors, and fibrosis assessment, and recommendations are given by experts from across the region. Simplified diagnostic algorithms and treatment regimens for both HIV co-infected and hepatitis C mono-infected patients are suggested. The recommendations are consensus based and provided to guide the development of programmes in sub-Saharan Africa. Political will and appropriate funding will be required to provide impetus to implement these recommendations.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29132760     DOI: 10.1016/S2468-1253(17)30249-2

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  26 in total

Review 1.  A Path to Ending Hepatitis C in Ethiopia: A Phased Public Health Approach to Achieve Micro-Elimination.

Authors:  Belaynew Wasie Taye
Journal:  Am J Trop Med Hyg       Date:  2019-11       Impact factor: 2.345

Review 2.  Therapeutic Advances in Viral Hepatitis A-E.

Authors:  Navroop Nagra; Richard A Kozarek; Blaire E Burman
Journal:  Adv Ther       Date:  2022-02-27       Impact factor: 3.845

3.  Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.

Authors:  Matthew J Akiyama; Charles M Cleland; John A Lizcano; Peter Cherutich; Ann E Kurth
Journal:  Lancet Infect Dis       Date:  2019-09-17       Impact factor: 25.071

4.  The Opioid Epidemic in Africa And Its Impact.

Authors:  Ann E Kurth; Peter Cherutich; Rosabelle Conover; Nok Chhun; R Douglas Bruce; Barrot H Lambdin
Journal:  Curr Addict Rep       Date:  2018-10-30

5.  Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges.

Authors:  Blessing Dzingirai; Leolin Katsidzira; Celia Moffat Joel Matyanga; Maarten Jacobus Postma; Marinus van Hulst; Nyashadzaishe Mafirakureva
Journal:  J Viral Hepat       Date:  2021-04-09       Impact factor: 3.728

6.  Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya.

Authors:  Matthew J Akiyama; Lindsey R Riback; Mercy Nyakowa; Helgar Musyoki; John A Lizcano; Abbe Muller; Chenshu Zhang; Josephine G Walker; Jack Stone; Peter Vickerman; Peter Cherutich; Ann E Kurth
Journal:  J Viral Hepat       Date:  2022-03-15       Impact factor: 3.517

7.  An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis.

Authors:  Nyashadzaishe Mafirakureva; Jack Stone; Hannah Fraser; Yvonne Nzomukunda; Aron Maina; Angela W Thiong'o; Kibango Walter Kizito; Esther W K Mucara; C Inés González Diaz; Helgar Musyoki; Bernard Mundia; Peter Cherutich; Mercy Nyakowa; John Lizcano; Nok Chhun; Ann Kurth; Matthew J Akiyama; Wanjiru Waruiru; Parinita Bhattacharjee; Charles Cleland; Dmytro Donchuk; Niklas Luhmann; Anne Loarec; David Maman; Josephine Walker; Peter Vickerman
Journal:  Addiction       Date:  2021-07-28       Impact factor: 6.526

8.  Hepatitis and tuberculosis testing are much less common than HIV testing among adults in Kisumu, Kenya: results from a cross-sectional assessment.

Authors:  Joshua Tunnage; Adam Yates; Chiaka Nwoga; Valentine Sing'oei; John Owuoth; Christina S Polyak; Trevor A Crowell
Journal:  BMC Public Health       Date:  2021-06-15       Impact factor: 3.295

9.  Hepatitis C in Uganda: Identification of infected blood donors for micro-elimination.

Authors:  Joan Nankya-Mutyoba; Betty S Apica; Grace Otekat; Dorothy B Kyeyune; Lourita Nakyagaba; Joletta Nabunje; Mary Nakafeero; Emmanuel Seremba; Ponsiano Ocama
Journal:  J Virus Erad       Date:  2021-05-11

10.  Sero-epidemiology and associated factors of HIV, HBV, HCV and syphilis among blood donors in Ethiopia: a systematic review and meta-analysis.

Authors:  Mulugeta Melku; Sintayehu Ambachew; Bamlaku Enawgaw; Molla Abebe; Zegeye Abebe; Tekalign Deressa; Debasu Damtie; Belete Biadgo; Belay Tessema; Demeke Geremew; Asemarie Kebede; Berhanu Woldu; Takele Teklu; Elias Shiferaw
Journal:  BMC Infect Dis       Date:  2021-08-09       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.